Oxford Biomedica, a gene and cell therapy group, has amended and expanded the License and Clinical Supply Agreement with Juno Therapeutics, Inc., a wholly owned subsidiary of Bristol Myers Squibb. The amendment relates to the initiation of two new viral vector programs for Bristol Myers Squibb CAR-T therapies.
 
The agreement, announced in March 2020, granted Juno a non-exclusive license to Oxford Biomedica’s LentiVector platform to be used for the manufacture of viral vectors for CAR-T and TCR-T programs in oncology and other indications.
 
Under amended terms, Oxford Biomedica will receive an undisclosed target nomination fee, as well as potential payments upon the achievement of certain milestones.
 
Dr. Roch Doliveux, Chair and Interim CEO of Oxford Biomedica commented: “Bristol Myers Squibb is a strategically important partner to Oxford Biomedica and we are pleased to announce this expansion of our License & Clinical Supply Agreement. BMS is a proven commercial and clinical leader in the CAR-T field and we are pleased to announce the initiation of the two new programmes, taking the number of programmes we are working on with BMS to six. We look forward to announcing further updates on this important partnership in due course.”